Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

v2.4.0.6
Commitments and Contingencies (Details Textual) (USD $)
 1 Months Ended 12 Months Ended
Nov. 15, 2012
sqft
Dec. 31, 2012
Employee
sqft
Dec. 31, 2011
Commitments and Contingencies (Textual) [Abstract]      
License agreement Date   Jun. 22, 2000  
Patent right filling date   Jun. 07, 1995  
Patent effective date   Mar. 04, 1997  
Patent Right Expire Date   Jun. 07, 2015  
Number of shares issued   599,940  
Company obligation to pay from percentage of selling price of product   5.00%  
Company obligation to pay from all revenue receive from sublicenses   20.00%  
License agreement amount   $ 50,000  
Minimum Royalty payment to UFRF   100,000  
Royalty payment to UFRF in installment   25,000  
Company obligated to spend on research and development, regulatory   1,000,000  
Company will pay on Quarterly basis out of gross profit   25.00%  
Company obligation to pay from all revenue receive from sublicenses   50.00%  
Voluntary channel agreement   18 months  
Channel agreement   12 months  
Termination Notice Period   90 days  
Percentage of number of shares of common stock equal to Base Shares   1.00%  
Maximum percentage of primary investment securities to investment of shares issued   10.00%  
Number of employees occupying leased office space   7  
Operating Leased Assets [Line Items]      
Period of lease     3 years
Percentage of insurance exceed   3.00%  
Deposit made   9,360  
Monthly lease payments   9,922  
Rent expense   119,064 108,758
Area of lease 4,168 3,150  
Lease expiration date Nov. 30, 2013 Nov. 30, 2012  
Office Space [Member]
      
Operating Leased Assets [Line Items]      
Period of lease   40 months  
Monthly lease payments   5,276  
Rent expense   58,036 63,312
Number of employees occupying leased office space   7  
Office Space Lease Two [Member]
      
Operating Leased Assets [Line Items]      
Period of lease   12 months 15 days  
Monthly lease payments 4,831    
Rent expense   $ 7,246  
Number of employees occupying leased office space   7  
Filing of First Investigational New Drug Application [Member]
      
Commitments and Contingencies (Textual) [Abstract]      
Percentage of number of shares of common stock equal to Base Shares   2.50%  
First Regulatory Approval of Oragenics Product [Member]
      
Commitments and Contingencies (Textual) [Abstract]      
Percentage of number of shares of common stock equal to Base Shares   3.00%  
Clinical study Phase 2 [Member]
      
Commitments and Contingencies (Textual) [Abstract]      
Percentage of number of shares of common stock equal to Base Shares   1.50%  
Clinical study Phase 3 [Member]
      
Commitments and Contingencies (Textual) [Abstract]      
Percentage of number of shares of common stock equal to Base Shares   2.00%  
UFRF [Member]
      
Commitments and Contingencies (Textual) [Abstract]      
License Agreement Date First Amended   Sep. 15, 2000  
License Agreement Date Second Amended   Jul. 10, 2002  
License Agreement Date Third Amended   Sep. 25, 2002  
License Agreement Date Fourth Amended   Mar. 17, 2003  
Intrexon [Member]
      
Commitments and Contingencies (Textual) [Abstract]      
Number of shares issued   4,392,425  
MU1140 [Member]
      
Commitments and Contingencies (Textual) [Abstract]      
License Agreement Date First Amended   Sep. 15, 2000  
License Agreement Date Second Amended   Jul. 10, 2002  
License Agreement Date Third Amended   Sep. 25, 2002  
License Agreement Date Fourth Amended   Mar. 17, 2003  
Smart Replacement Therapy [Member]
      
Commitments and Contingencies (Textual) [Abstract]      
License agreement Date   Aug. 04, 1998